PF-05241328

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePF-05241328
Drug Alias NamePF-05241328
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type IX alpha subunit blockers
TargetsSodium channel protein type IX alpha subunit
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A